GALT:NSC-Galectin Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 2.87

Change

+0.16 (+5.90)%

Market Cap

USD 0.03B

Volume

0.14M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-6.33 (-0.55%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-8.17 (-1.67%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

+4.09 (+1.51%)

USD 34.71B
ARGX argenx NV ADR

-15.72 (-2.92%)

USD 32.33B
MRNA Moderna Inc

+2.82 (+4.08%)

USD 26.25B
SMMT Summit Therapeutics PLC

-3.26 (-11.06%)

USD 23.47B
BGNE BeiGene Ltd

+1.06 (+0.54%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.69 (+0.99%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+0.04 (+0.01%)

USD 15.09B

ETFs Containing GALT

CHDIV:SW UBS ETF (CH) - MSCI Switz.. 6.87 % 0.00 %

-0.01 (-0.04%)

USD 1,244,681.59B
FSZ First Trust Switzerland A.. 4.23 % 0.80 %

-0.08 (-0.04%)

USD 0.08B
EESM:PA BNP Paribas Easy MSCI Eur.. 2.07 % 0.00 %

+0.84 (+-0.04%)

USD 0.14B
EESM:XETRA BNP Paribas Easy MSCI Eur.. 2.07 % 0.00 %

+0.65 (+-0.04%)

USD 0.22B
CEM:PA Amundi MSCI Europe Small .. 0.79 % 0.00 %

+0.74 (+-0.04%)

USD 0.13B
X026:XETRA Amundi MSCI Europe Small .. 0.79 % 0.00 %

+0.22 (+-0.04%)

USD 0.11B
EESM:F BNP Paribas Easy - MSCI E.. 0.00 % 0.00 %

+2.55 (+-0.04%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 72.89% 86% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.89% 86% B+ 93% A
Trailing 12 Months  
Capital Gain 63.07% 82% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.07% 81% B- 89% A-
Trailing 5 Years  
Capital Gain -20.50% 64% D 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.50% 64% D 35% F
Average Annual (5 Year Horizon)  
Capital Gain 9.25% 65% D 65% D
Dividend Return 9.25% 65% D 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.74% 41% F 22% F
Risk Adjusted Return 11.75% 72% C 49% F
Market Capitalization 0.03B 55% F 46% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 207.70 1% 0%
Price / Cash Flow Ratio -5.09 67% 78%
Price/Free Cash Flow Ratio -4.04 75% 80%
Management Effectiveness  
Return on Equity -3,727.95% 1% 1%
Return on Invested Capital -437.33% 7% 2%
Return on Assets -103.87% 8% 3%
Debt to Equity Ratio -119.09% 87% 93%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector